Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

Yaringaño, Jesús; Mascaro-Baselga, Pau; Benito, Pau; Núñez, Fidel; Roca Herrera, Maria; Eremiev, Simeón; Benavente, Sergi; Pimentel, Isabel

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Yaringaño, Jesús
dc.contributor.author	Mascaro-Baselga, Pau
dc.contributor.author	Benito, Pau
dc.contributor.author	Núñez, Fidel
dc.contributor.author	Roca Herrera, Maria
dc.contributor.author	Eremiev, Simeón
dc.contributor.author	Benavente, Sergi
dc.contributor.author	Pimentel, Isabel
dc.date.accessioned	2025-02-25T07:24:40Z
dc.date.available	2025-02-25T07:24:40Z
dc.date.issued	2024-08-12
dc.identifier.citation	Yaringaño J, Roca-Herrera M, Eremiev S, Mascaró-Baselga P, Benito P, Núñez F, et al. Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report. Front Oncol. 2024 Aug 12;14:1378248.
dc.identifier.issn	2234-943X
dc.identifier.uri	https://hdl.handle.net/11351/12644
dc.description	Conjugat anticòs-medicament; Carcinomatosi leptomeníngea; Càncer de mama triple negatiu
dc.description.sponsorship	The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding from.Vall d'Hebron Institute of Oncology (VHIO) made possible the publication of this article.
dc.language.iso	eng
dc.publisher	Frontiers Media
dc.relation.ispartofseries	Frontiers in Oncology;14
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer - Tractament
dc.subject	Anticossos monoclonals - Ús terapèutic
dc.subject	Metàstasi
dc.subject	Sistema nerviós central - Càncer - Tractament
dc.subject.mesh	Antibodies, Monoclonal, Humanized
dc.subject.mesh	Immunoconjugates
dc.subject.mesh	/therapeutic use
dc.subject.mesh	Triple Negative Breast Neoplasms
dc.subject.mesh	Meningeal Carcinomatosis
dc.subject.mesh	/drug therapy
dc.title	Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.3389/fonc.2024.1378248
dc.subject.decs	anticuerpos monoclonales humanizados
dc.subject.decs	inmunoconjugados
dc.subject.decs	/uso terapéutico
dc.subject.decs	neoplasias de mama triple negativos
dc.subject.decs	carcinomatosis meníngea
dc.subject.decs	/farmacoterapia
dc.relation.publishversion	https://doi.org/10.3389/fonc.2024.1378248
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Yaringaño J, Roca-Herrera M, Eremiev S, Mascaró-Baselga P, Benito P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Núñez F] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Benavente S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pimentel I] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	39188688
dc.identifier.wos	001297195500001
dc.rights.accessrights	info:eu-repo/semantics/openAccess